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Abstract We have isolated and characterized a novel rat 
placental pre-proGHRH mRNA (pre-proGHRH-2 mRNA). 
This mRNA is generated by an alternative splicing process 
which results in the presence of an additional exon of 156 bp 
(designated exon 4.5) located between exons 4 and 5 of the 
previously reported hypothalamic and placental pre-proGHRH 
mRNA (pre-proGHRH-1 mRNA). Since the sequences encoding 
mature GHRH are included within exons 3 and 4, the processing 
of pre-proGHRH-2 would not affect the synthesis of mature 
GHRH but would generate a C-terminal peptide (designated 
GCTP-2) different from that previously reported in the 
hypothalamus and placenta (GCTP-1). The putative GCTP-2 
has 64 amino acids, and the firs I 18 N-terminal residues are 
identical to those present in GCTP-1 (30 amino acids long). Pre-
proGHRH-2 mRNA has not been detected in the hypothalamus. 
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1. Introduction 
Growth hormone-releasing hormone ( G H R H ) is a hypo-
thalamic peptide that plays a critical role in controlling the 
synthesis and secretion of growth hormone by the anterior 
pituitary. H u m a n G H R H is a C-terminal amidated peptide 
of 44 amino acids, which was initially isolated from pancreatic 
tumors [1,2]. The primary sequence of hypothalamic G H R H 
has been established in other species, most of which show 
great similarity [3]. In contrast, rat G H R H is a 43 amino 
acid long, non-amidated peptide, which is only 67% homolo-
gous with human G H R H [4,5]. After cloning of the corre-
sponding human cDNA, it was established that G H R H orig-
inates from a precursor (p re -proGHRH) that is processed to 
mature G H R H by removal of the signal peptide and proteo-
lytic cleavage at the C-terminal region [6-8]. A model for the 
processing of human p re -p roGHRH in transgenic mice has 
been proposed [9]. 
G H R H has also been detected in non-neural extrahypotha-
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lamic tissues of different species. In particular, G H R H expres-
sion in placenta has been reported in rat [10-14], mouse 
[12,15] and human [16]. Ra t placenta contains a pre-
p r o G H R H m R N A which encodes a p r e - p r o G H R H identical 
to that found in the hypothalamus [14]. Nevertheless, the 
placental and the hypothalamic G H R H m R N A s differ in 
the region corresponding to the untranslated exon 1 because 
of the use of an alternative promoter in the placenta, located 
10 kb upstream from the hypothalamic promoter [14]. In the 
rat, G H R H is encoded by a single copy gene organized into 
six small exons spanning over 20 kb of genomic D N A [14,17]. 
Exons 2-5 are contained in both hypothalamic and placental 
G H R H m R N A , while exon 1 is specific to placenta or hypo-
thalamus (exon IP and 1H, respectively). 
The processing of p r e - p r o G H R H is mediated by endopro-
teolytic cleavages directed by arginines flanking the mature 
G H R H [6,9]. In the hypothalamus, and also probably in pla-
centa, this processing yields mature G H R H and a C-terminal 
flanking peptide (designated GCTP) of uncertain function. 
H u m a n G C T P has been co-localized with G H R H in hypo-
thalamic neurons [18] and has been suggested to be involved 
in the control of feeding behavior [19]. 
Here we present evidence for the expression in rat placenta 
of a novel form of p r e - p r o G H R H m R N A generated by a 
differential splicing process. This form of p r e - p r o G H R H 
m R N A encodes a p r e - p r o G H R H with a different C-terminal 
flanking peptide. 
2. Materials and methods 
2.1. Preparation of samples 
Female Sprague-Dawley rats weighing 200-230 g were caged over-
night with males and the presence of a copulation plug was verified 
the following morning, which was considered day 0 of pregnancy. 
Fetuses from days 13 to 20 of gestation were exteriorized by cae-
sarean section and killed by decapitation. Tissues were removed, fro-
zen on liquid nitrogen and stored at —80°C until used. 
2.2. cDNA cloning from a rat placenta cDNA library 
A rat long-term placenta cDNA library constructed in the vector 
JigtlO [20] was screened under high stringency hybridization condi-
tions using as a probe the insert of the cDNA clone Ä.rpGHRH-1 
corresponding to the rat placental GHRH mRNA previously de-
scribed [14]. Positive clones were purified and their inserts were sub-
cloned into Bluescript plasmids (Stratagene). 
2.3. Reverse transcription of total RNA, PCR amplification of cDNA 
and cloning of PCR products 
Total RNA was isolated from rat placenta by the guanidinium 
thiocyanate method [21]. For the reverse transcription reaction, 2 (ig 
of rat hypothalamic or placental total RNA in 3.75 ul of water was 
incubated at 65°C for 2 min, quenched on ice and adjusted to a final 
volume of 10 ul containing 1 XPCR buffer (50 mM KC1, 10 mM Tris-
HC1, pH 9.0, 0.02% Triton X-100), 2.5 mM MgCl2, 1 Hg of bovine 
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serum albumin (Promega), 0.5 ug oligo(dT) (Promega), 10 units of 
RNasin (Promega), 200 |xM each dNTP (Boehringer Mannheim) and 
200 units of M-MLTV reverse transcriptase (Boehringer Mannheim). 
After incubation for 60 min at 42°C, the enzyme was inactivated at 
95°C for 15 min, and samples were stored at 4°C until use. 
Two oligonucleotides were used for PCR amplification of cDNA: 
an upstream primer, corresponding to sequences located in exon 2 (5'-
GAGTGAAGGATGCCACTCTGGG-3') and a downstream primer, 
complementary to sequences within exon 5 (5'-CCGAGGGCTCAA-
GCCTCCGC-3') (Fig. 1). 3 ul of the previously obtained cDNA re-
action was diluted to a final volume of 50 ul containing 50 mM KC1, 
10 mM Tris-HCl, pH 9.0, 0.02% Triton X-100, 2 mM MgCl2, 50 uM 
each dNTP, and 0.4 uM of each primer. Samples were overlaid with 
half a volume of mineral oil. After 2 min at 94°C, the temperature was 
lowered to 80°C and 1 ul of 1 X PCR buffer containing 1 U of Taq 
polymerase (Promega) was added. Thirty cycles of amplification were 
carried out in a Programmable Thermal Controller (MJ Research, 
Inc.) using a cycling program of 94°C for 1 min, 68°C for 1 min, 
and 72°C for 1 min, followed by a 5 min final extension at 72°C. 
PCR products were fractionated by agarose gel electrophoresis, puri-
fied and cloned into the pGEM-T plasmid (Promega) according the 
manufacturer's instructions. Densitometric analysis of the ethidium 
bromide stained DNA fragments following agarose gel electrophoresis 
was performed in a CUE-2 Image Analyzer (Olympus). 
For mapping exon 4.5, we performed long PCR amplification (Ex-
pand Long Template PCR System from Boehringer Mannheim) using 
the exon 2 and exon 5 specific primers previously described (Fig. 1). 
The PCR amplified product was further amplified for exon 4 to 4.5, 
exon 4.5 to 5 and exon 4 to 5 using specific primers (5'-GCAGAG-
GACAAGCAGATGG-3', exon 4 upstream; 5'-TACAGCGGCAG-
GAGACACT-3', exon 4.5 downstream; 5'-CCAGCACATAAAA-
GAACACA-3', exon 4.5 upstream). 
2.4. DNA sequencing 
The cDNA subclones and the PCR cloned products were sequenced 
by the dideoxynucleotide chain termination method using T7 DNA 
polymerase [22,23] (United States Biochemical Corporation). 
2.5. Northern blot analysis 
Total hypothalamic and placental RNA was obtained from 
Sprague-Dawley rats on gestational days 18-20 by successive phe-
nol/chloroform and chloroform extraction of the frozen ground tis-
sues, followed by ethanol and lithium chloride precipitation [22,23]. 
RNA samples (10 ug) were fractionated by electrophoresis on 1% 
agarose/formaldehyde gels, transferred to nylon membranes (Nytran, 
Schleicher and Schuell) and hybridized with the 32P-radiolabeled 
Avall-HinQ fragment of the novel placental GHRH cDNA probe 
(Fig. 1) according to standard procedures [22,23]. 
2.6. Southern blot analysis 
PCR amplified products were fractionated by electrophoresis on 1% 
agarose/formaldehyde gels, transferred to nylon membranes (Nytran, 
Schleicher and Schuell) and hybridized with the 32P-radiolabeled rat 
placental pre-proGHRH-1 cDNA [14] according to standard proce-
dures [22,23]. 
3. Results 
A c D N A clone (ÄjpGHRH-2) corresponding to a novel 
form of p r e - p r o G H R H m R N A (referred to as pre-
p r o G H R H - 2 m R N A ) was isolated after screening a XgtlO 
rat placenta c D N A library. Fig. 1 shows the nucleotide se-
quence of the 495 bp EcoRl insert present in Ä.rpGHRH-2. 
P re -p roGHRH-2 m R N A has an open reading frame of 414 
bp, which encodes a p r e - p r o G H R H of 138 amino acids that is 
different from that previously reported in the hypothalamus 
and placenta [14,17]. This novel form of p r e - p r o G H R H 
m R N A is generated by an alternative splicing process which 
results in the presence of an additional exon of 156 nt (re-
ferred to as exon 4.5) located between exons 4 and 5 in the 
G H R H m R N A s described previously [14,17]. Exon 4.5 has an 
open reading frame, following that of exon 4, that encodes 46 
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CCCGCCCAGGAGTGAACCATCCCACTCTCGGTGTTCTTTG1GCTCCTCACCCTCACCAGTGGCTCCCAC 51 
KetFroLGUxrpValPhePheValLeuLeuThrLeuThrSerGlySerHis 
E3 f 
TGCTCACTGCCCCCCTCACCTCCCTTCAGGGTGCGGCGGCATGCAGACGCCATCTTCACCAGCAGCTAC 120 
CysSarLeuProProserProProPheArgValArgArgfii sAlaAspAIa l l e P h e T h z S e r S e z T y z 
CGGAGAATCCTGGGCCAATTATATGCCCGCAAACTGCTGCACGAAATCATGAACAGGCAGCAAGGGGAG 18 9 
ArgArglleLeuGlyGlnLeuTyrAlaArgLysLeuLeuHisGluIleMetAsnArgGlnGlnGlyGlu 
AGGAACCAGGAACAAAGATCCAGGTTCAACCGCCATTTGGACAGAGTGTGGGCAGAGGACAAGCAGATG 2 58 
ArgAsnGInGltiGlnArgSerArg-pheAsnArgHisLeuAspArgValTrpAlaGluAspLysGlnKet 
^Aval I —«-24 . 5 
GCCCTGGAGAGCATCTl^GTCC^GCAACGCAGTGTCCCAAGATATGTGGTAGATATCTTGGTGGAAACA 3 27 
AlaLeuGluSQrlleLeuValGlnGlnAraSerValProArqTvrLeuLguAspIlgLeuValGluThr 
CATCCCAACTCCTCGGCGGCCCAGTGTCTCCTGCCGCTGTACACTTTGCTACACTCAAACCAGCACATA 3 96 
HisProAsnSerSerAlaAlaGlnCvsLeuLeuProLeuTvrThrLeuLeuHisSerAsnGlnHisIle 
E5 Hinf 1 
AAAGAACACACAACACAATAACCTTTGACCCAATTGCAGGpATTCfcCAAGGATGAAGGTTTCAGCGGAG 4 6 5 
LvsGluHisThrThrGln 
GCTTGAGGGCTCG 
Fig. 1. Nucleotide sequence of the rat placenta pre-proGHRH-2 
cDNA clone. Nucleotides are numbered by assigning position +1 to 
the ATG initiator codon. The deduced amino acid sequence of the 
pre-proGHRH-2 is shown below the nucleotide sequence. The ma-
ture GHRH peptide is represented in italics. The amino acids en-
coded by exon 4.5 are underlined. The distribution of exons is indi-
cated by arrows on the basis of the previously characterized 
hypothalamic and placental pre-proGHRH mRNA [14,17], ^4vaII 
and Hinil restriction enzyme sites are boxed. The positions corre-
sponding to the oligonucleotide primers used for PCR amplification 
are dash underlined. 
amino acids (Fig. 1). The presence of a stop codon near the 
end of exon 4.5 avoids translation of exon 5. 
The occurrence of this novel p r e - p r o G H R H m R N A was 
confirmed by reverse transcription of rat placental total 
R N A followed by P C R amplification of the c D N A using spe-
cific primers for exons 2 and 5 of p r e - p r o G H R H m R N A (see 
Fig. 1 and Section 2). Electrophoretic analysis of the P C R 
amplified products showed two D N A bands of about 330 
and 490 bp (Fig. 2). The amplified fragments were purified 
and cloned into a plasmid vector. Sequence analysis revealed 
c D N A inserts of 488 bp and 332 bp corresponding respec-
tively to the p re -p roGHRH-2 m R N A and the placental pre-
p r o G H R H - 1 m R N A previously reported [14]. The densito-
metric analysis of the P C R products obtained at different 
cycles of amplification (10-30 cycles) indicated that the rela-
tive abundance of the 488 bp fragment is about 10% the 
amount of the 332 bp fragment (data not shown). 
Nor thern blot analysis of hypothalamic and placental total 
R N A using an exon 4.5 specific probe (Avall-Hinil fragment, 
Fig. 1) revealed that the p re -p roGHRH-2 transcript was de-
tected in placenta but not in the hypothalamus (Fig. 2A). 
These results were further confirmed by RT -PCR analysis of 
hypothalamic R N A , where a single 332 bp fragment was am-
plified (Fig. 2B,C). The 488 bp band detected in the placenta 
was never detected in the hypothalamus, even after increasing 
the number of cycles of the P C R or by longer exposures of the 
corresponding Southern blots (data not shown). Pre-
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Fig. 2. Expression of rat pre-proGHRH niRNAs. A: Northern blot 
analysis of rat hypothalamic (lane 1) and placental (lane 2) total 
RNA (10 ug) using as a probe the Avall-Hinñ fragment corre-
sponding to exon 4.5 (see Fig. 1). The approximate size of the hy-
bridizing transcript is shown. B: Ethidium bromide staining after 
agarose gel electrophoresis of RT-PCR amplification products of rat 
hypothalamic (lane 1) and placental (lane 2) pre-proGHRH 
mRNAs. The approximate size of RT-PCR amplified cDNA frag-
ments is indicated. C: Southern blot analysis of the agarose gel con-
taining the PCR amplification products of rat hypothalamic (lane 1) 
and placental (lane 2) pre-proGHRH mRNAs shown in B. Time ex-
posure was 3 days. 
proGHRH-2 mRNA was detected in the placenta at 14, 16, 
18, 20 and 21 days of gestation (data not shown). 
The relative position of exon 4.5 in respect to exons 4 and 5 
has been mapped by PCR using exon specific primers (for 
details, see Section 2). Exon 4.5 is located 1.7 kb downstream 
of exon 4 and 800 bp upstream of exon 5 (Fig. 3). 
The biological significance of the pre-proGHRH-2 is cur-
rently unknown, although its processing to yield mature 
GHRH according to the model proposed by Brar et al. [9] 
would result in the synthesis of a C-terminal peptide (here 
referred to as GCTP-2) different from that generated in the 
hypothalamus [18], and also suggested to occur in the placen-
ta [14]. The putative placental GCTP-2 has 64 amino acids, 
the first 18 N-terminal residues being identical in GCTP-1 and 
GCTP-2 (Fig. 4). 
A computer search against the GenEMBL databank re-
vealed that the amino acid sequence encoded by exon 4.5 
has no significant similarity to any previously reported pro-
tein. Nevertheless, high levels of similarity were detected at the 
DNA level with two particular sequences corresponding to the 
non-coding regions of UDP glucuronosyltransferase [24], ly-
sozyme gene [25] and the kallikrein-like serine protease [26]. 
In addition, the núcleo tide sequence of exon 4.5 also shows 
significant similarity with the rat 1B12 repetitive element [27]. 
4. Discussion 
It is well documented that the placenta synthesizes a variety 
of peptide and steroid hormones having essential roles during 
pregnancy [28]. In addition, the placenta produces hormones, 
growth factors and cytokines that are also synthesized in oth-
er tissues [29,30], among them a number of hypothalamic 
peptides, including GHRH. Immunodetection of GHRH 
was first shown in rat placenta by Meigan et al. [11]. Expres-
sion of the GHRH gene in placenta was further demonstrated 
in rat [10,12-14], mouse [12,15] and human [16]. The rat pla-
cental pre-proGHRH mRNA contains an open reading frame 
that encodes a polypeptide identical to the hypothalamic pre-
proGHRH [14]. Nevertheless, the placental and the hypo-
thalamic GHRH mRNAs differ in the region corresponding 
to the untranslated exon 1 because of the use in the placenta 
of an upstream alternative promoter. A combined mechanism 
involving the use of tissue-specific alternative promoters and 
the differential splicing of exon 1 generates the mature GHRH 
transcript in placenta and hypothalamus [14]. 
Here we present evidence for the presence in rat placenta of 
a pre-proGHRH mRNA different from that previously char-
acterized [14]. This novel pre-proGHRH mRNA (pre-
proGHRH-2 mRNA) has an additional exon (designated 
exon 4.5) of 156 bp, located between exons 4 and 5, and 
contains an open reading frame encoding a pre-proGHRH 
form of 138 amino acids (Fig. 1). Since the sequences encod-
ing mature GHRH are included within exons 3 and 4, the 
expected processing of the pre-proGHRH-2 would not affect 
the synthesis of mature GHRH but would generate a novel C-
terminal peptide (designated GCTP-2) (Fig. 4) different from 
that previously reported in hypothalamus and placenta 
(GCTP-1). 
This novel pre-proGHRH mRNA found in placenta was 
not detected in the hypothalamus (Fig. 2). The relatively 
high level of pre-proGHRH-2 mRNA during the second 
half of gestation suggests that it may significantly contribute 
to the synthesis in placenta of both mature GHRH and 
GCTP-2. 
It is well established that many peptide hormones and neu-
ropeptides are produced from large inactive precursors 
through endoproteolytic cleavage at sites usually marked by 
paired basic residues (primarily Lys-Arg and Arg-Arg) or oc-
casionally by monobasic residues (primarily Arg) [31,32]. A 
detailed analysis of the primary sequence of pre-proGHRH-1 
and pre-proGHRH-2 reveals that they contain a high propor-
tion of dibasic and monobasic sites, thus providing the possi-
bility of a variety of alternative processing events. In this 
respect, the Chromatographie detection in placenta, but not 
in the hypothalamus, of an additional peak of high molecular 
weight (about 10 kDa) showing GHRH immunoreactivity [11] 
suggested that other GHRH-like polypeptides may be present 
in rat placenta. To date, the molecular nature of this high 
molecular weight GHRH immunoreactive material has not 
been established. ProGHRH-1, which contains 74 amino acids 
A 
1P 1H 2 3 4 4.5 5 
—I 1 H—I—H— 
1 kb 
B 
Hypothalamus 
Placenta 
Fig. 3. Genomic organization of rat GHRH gene. A: Schematic 
representation of the rat GHRH gene. Exons are represented by 
boxes and named according to nomenclature indicated in text. Exon 
sizes are not drawn to scale. B: Structure of mature GHRH tran-
scripts in hypothalamus and placenta. Untranslated regions are rep-
resented by open boxes; translated regions are represented by dark 
boxes. 
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pre-proGHRH1 Q 
signal peptide GHRH 
pre-proGHRH2 Q 
Hl DRVWAFnKQMAI FSII QGFPHMKI SAFA 
GCTP-1 
W///////M 
GCTP 
, . . - - GCTP-2 
HLDRVWAEDKQMALESIl VQQHSVPRYI I nil VFTHRNSSAAOCI I PI YTI I HSNOHIKFHTTn 
Fig. 4. Schematic representation of rat placental pre-proGHRH-1 
and pre-proGHRH-2. The amino acid sequences of GCTP-1 and 
GCTP-2 are shown. Identical residues in GCTP-1 and GCTP-2 are 
underlined. 
and has an estimated molecular size of 9 kDa, would repre-
sent a good candidate. Nevertheless, the involvement of the 
novel form of p r e - p r o G H R H cannot be ruled out. In this 
respect, the analysis of the different processing possibilities 
of p re -p roGHRH-2 directed by dibasic amino acids predicts 
a peptide of 87 residues with an estimated molecular size of 
10.3 kDa . This peptide, extending from residue 22 of mature 
G H R H (flanked by the dibasic site Arg-Lys) to the end of 
GCTP-2, should display both immunoreactivity against 
G H R H and the appropriate molecular weight. 
The physiological significance of the hypothalamic and pla-
cental GCTP-1 has not been assessed, although it has been 
reported that human hypothalamic G C T P influences the feed-
ing behavior of rats when injected into the brain [19]. Fur-
thermore it has been shown that GCTP-1 is co-secreted with 
G H R H in rat hypothalamic neurons [18]. The data presently 
available on placental GCTP-2 do not indicate whether it 
might have a functional role during pregnancy as a processed 
peptide or, alternatively, promote a differential processing 
and/or stability of the corresponding p re -p roGHRH, thus reg-
ulating the synthesis of either mature G H R H or GHRH-l ike 
peptides. Additional experiments are needed to assign the 
physiological role of the novel placental p r e - p r o G H R H re-
ported here. 
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